光动力疗法与PD-1/PD-L1抑制剂联合抗肿瘤治疗的研究进展

Research progress on photodynamic therapy combined with PD-1/PD-L1 inhibitors in anti-tumor therapy

光动力疗法已经成为多种肿瘤辅助治疗的重要选择之一。近年来,针对免疫检查点的单克隆抗体已显示出对一系列癌症的临床治疗前景。将光动力疗法与免疫检查点抑制剂相结合的治疗方案有助于扩大治疗效果并最大限度地减少不良反应,已经在动物及人体研究中显示出初步的联合抗肿瘤效果。该文综述光动力疗法联合免疫检查点抑制剂在乳腺癌、结直肠癌、肾细胞癌、恶性黑素瘤等恶性肿瘤中的抗肿瘤及免疫学效应,为优化抗肿瘤联合治疗方案提供理论基础。

Photodynamic therapy has become one of the important options for adjuvant therapy of various tumors.In recent years,monoclonal antibodies targeting immune checkpoints have shown the clinical promise in a range of cancers.Treatment regimens that combine photodynamic therapy with immune checkpoint inhibitors help to amplify therapeutic effects and minimize side effects,and have shown preliminary combined anti-tumor efficacy in animal and human studies.In this article,the anti-tumor effect,as well as the immunological changes after the combined treatment with photodynamic therapy and immune checkpoint inhibitors in breast cancer,colorectal cancer,renal cell carcinoma,malignant melanoma and other malignant tumors were reviewed,aiming to provide a theoretical basis for the optimization of anti-tumor combination therapy.